Hobart Private Capital’s Boston Scientific BSX Stock Holding History

Hobart Private Capital’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,356	Closed	-$1.27M	–	133
2025 Q4	$1.27M	Buy	13,356 +5,841	+78%	+$573K	0.25%	63
2025 Q3	$734K	Buy	7,515 +2,220	+42%	+$230K	0.15%	75
2025 Q2	$569K	Buy	5,295 +2,979	+129%	+$301K	0.13%	73
2025 Q1	$234K	Buy	+2,316	New	+$233K	0.06%	90

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Hobart Private Capital's BSX Position: Q1 2026 in Review

Hobart Private Capital sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 13,356 shares — an estimated $1.27M sold.

Hobart Private Capital first reported a position in BSX in Q1 2025 and held it in 4 quarters. The position peaked at $1.27M in Q4 2025. 1,676 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Hobart Private Capital reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
Hobart Private Capital sold 13,356 Boston Scientific shares in Q1 2026, an estimated $1.27M.
Hobart Private Capital first reported a position in Boston Scientific in Q1 2025 and held it in 4 quarters.
Hobart Private Capital's Boston Scientific position peaked at $1.27M in Q4 2025.
1,676 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Hobart Private Capital's 13F filing for Q1 2026, filed 7 Apr 2026.